RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO

RxSight, Inc.

Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.
Net loss $(13.5)M ($(3.28)/share basic); adjusted net loss $(13.3)M ($(3.24)/share).
Gross loss $(0.8)M due to $1.7M inventory reserve for updated LAL with ActivShield.
Completed IPO in July 2021 raising ~$120M net proceeds; cash & equivalents $61.7M at June 30.
FDA approval and launch of LAL with ActivShield technology; new VP of U.S. Sales appointed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.